Importantly, we are now in the planning stages for multiple Phase 1 clinical trials with COTI-2, including for gynecologic cancers and for recurrent head and neck cancers.
"COTI-2 represents a potential breakthrough treatment for recurrent head and neck cancers. We are energized by the potential for COTI-2 given the central importance of p53 gene mutations in the most difficult to treat HNSCC tumors. Based on our preclinical test data and the substantial unmet medical need, we are now in the planning stages for a Canadian Phase 1 clinical trial of oral COTI-2 in patients with recurrent HNSCC, led by the Head and Neck Surgical Oncology team at Western's Schulich School of Medicine & Dentistry."
- Dr. Wayne Danter, President and CEO